Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $4 | $4 | $7 |
| G&A Expenses | $0 | $0 | $3 | $6 |
| SG&A Expenses | $1 | $4 | $3 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $8 | $7 | $12 |
| Operating Income | -$4 | -$8 | -$7 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$4 | -$9 | -$7 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$9 | -$7 | -$13 |
| % Margin | – | – | – | – |
| EPS | -0.048 | -0.097 | -0.074 | -0.15 |
| % Growth | 50.3% | -31.1% | 50.9% | – |
| EPS Diluted | -0.048 | -0.097 | -0.074 | -0.15 |
| Weighted Avg Shares Out | 94 | 92 | 89 | 82 |
| Weighted Avg Shares Out Dil | 94 | 92 | 89 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$9 | -$7 | -$12 |
| % Margin | – | – | – | – |